Company
Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses. Cantex’s pipeline consists of two product candidates – DSTAT (formerly known as CX-01) and Dicopp®. Both drugs are in clinical development for diseases where innovative and more effective treatments are greatly needed.
16055
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16055,page-parent,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
 

Company

doctor reviewing MRI

ABOUT CANTEX PHARMACEUTICALS, INC.

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing novel treatments for inflammatory lung diseases and cancer.

 

Cantex’s pipeline consists of two product candidates – Dicopp® and DSTAT. Both drugs are in clinical development for diseases where innovative and more effective treatments are greatly needed.

 

Dicopp®, which is a proprietary combination of disulfiram + copper, is being developed for the treatment of long-term as well as short-term complications of COVID-19 infection. A Phase 2 study of Dicopp® as a treatment of the prolonged disabling complications of COVID-19 infection commonly known as “long-haul COVID-19”, as well as in the treatment of recently infected patients with mild to moderate symptoms of COVID-19 infection is expected to begin in 2021. In addition, Dicopp® will begin a trial in relapsed/refractory myeloma in early 2021.

 

DSTAT, licensed to Chimerix in July 2019, is being studied in two disease indications: COVID-19-associated acute lung injury (ALI) and acute myeloid leukemia (AML). Cantex remains involved in the continued development of DSTAT via a Joint Development Committee. In COVID-19 associated ALI, DSTAT is currently the subject of an ongoing Phase 2/3 clinical trial. DSTAT is also being studied as a potential treatment for AML. A randomized Phase 2 clinical trial in AML indicated that DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity. A Phase 3 clinical trial in AML will begin in early 2021.